These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27308826)

  • 21. Influence of mucolytic therapy on respiratory mechanics in patients with chronic obstructive pulmonary disease.
    Schreiber J; Bohnsteen B; Rosahl W
    Eur J Med Res; 2002 Mar; 7(3):98-102. PubMed ID: 11953279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
    Decramer M; Anzueto A; Kerwin E; Kaelin T; Richard N; Crater G; Tabberer M; Harris S; Church A
    Lancet Respir Med; 2014 Jun; 2(6):472-86. PubMed ID: 24835833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of the novel D2/beta2-agonist, Viozan (sibenadet HCl), in the treatment of symptoms of chronic obstructive pulmonary disease: results of a large-scale clinical investigation.
    Laursen LC; Lindqvist A; Hepburn T; Lloyd J; Perrett J; Sanders N; Rocchiccioli K
    Respir Med; 2003 Jan; 97 Suppl A():S23-33. PubMed ID: 12564608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
    Quinn D; Barnes CN; Yates W; Bourdet DL; Moran EJ; Potgieter P; Nicholls A; Haumann B; Singh D
    Pulm Pharmacol Ther; 2018 Feb; 48():71-79. PubMed ID: 28987804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of cetirizine dihydrochloride on the airway response to hypertonic saline aerosol in patients with chronic obstructive pulmonary disease (COPD).
    Grönke L; Schlenker J; Holz O; Out TA; Magnussen H; Jörres RA
    Respir Med; 2005 Oct; 99(10):1241-8. PubMed ID: 16140224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of nebulized N-acetylcysteine on the phlegm of chronic obstructive pulmonary disease: the NEWEST study.
    Rhee CK; Lim SY; Lee WY; Jung JY; Park YB; Lee CY; Hwang YI; Song JW; Choi WI; Yoo KH; Kim KU; Kim YI; Kim TH; Park SJ; Shin KC; Um SJ; Yoon HK; Lee HS; Kim DK; Leem AY;
    BMC Pulm Med; 2024 Sep; 24(1):434. PubMed ID: 39223526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term effects of budesonide on inflammatory status in COPD.
    Boorsma M; Lutter R; van de Pol MA; Out TA; Jansen HM; Jonkers RE
    COPD; 2008 Apr; 5(2):97-104. PubMed ID: 18415808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease.
    Pudi KK; Barnes CN; Moran EJ; Haumann B; Kerwin E
    Respir Res; 2017 Nov; 18(1):182. PubMed ID: 29096627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.
    Bhatt SP; Dransfield MT; Cockcroft JR; Wang-Jairaj J; Midwinter DA; Rubin DB; Scott-Wilson CA; Crim C
    Int J Chron Obstruct Pulmon Dis; 2017; 12():351-365. PubMed ID: 28176907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease.
    Maleki-Yazdi MR; Beck E; Hamilton AL; Korducki L; Koker P; Fogarty C
    Respir Med; 2015 May; 109(5):596-605. PubMed ID: 25829298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
    Singh D; Schröder-Babo W; Cohuet G; Muraro A; Bonnet-Gonod F; Petruzzelli S; Hoffmann M; Siergiejko Z;
    Respir Med; 2016 May; 114():84-90. PubMed ID: 27109816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations.
    Seemungal TA; Wilkinson TM; Hurst JR; Perera WR; Sapsford RJ; Wedzicha JA
    Am J Respir Crit Care Med; 2008 Dec; 178(11):1139-47. PubMed ID: 18723437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study.
    Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Xia QK; Gao Y; Zhong NS;
    COPD; 2013 Apr; 10(2):164-71. PubMed ID: 23061828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease.
    John M; Bosse S; Oltmanns U; Schumacher A; Witt C
    Respir Med; 2005 Nov; 99(11):1418-24. PubMed ID: 15894479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.
    Decramer ML; Chapman KR; Dahl R; Frith P; Devouassoux G; Fritscher C; Cameron R; Shoaib M; Lawrence D; Young D; McBryan D;
    Lancet Respir Med; 2013 Sep; 1(7):524-33. PubMed ID: 24461613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease.
    Barnes NC; Qiu YS; Pavord ID; Parker D; Davis PA; Zhu J; Johnson M; Thomson NC; Jeffery PK;
    Am J Respir Crit Care Med; 2006 Apr; 173(7):736-43. PubMed ID: 16424444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial.
    Watz H; Tetzlaff K; Magnussen H; Mueller A; Rodriguez-Roisin R; Wouters EFM; Vogelmeier C; Calverley PMA
    Respir Res; 2018 Dec; 19(1):251. PubMed ID: 30545350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.
    Beeh KM; Beier J; Candler H; Wittig T
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2877-2884. PubMed ID: 27920515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial.
    Neukamm A; Høiseth AD; Einvik G; Lehmann S; Hagve TA; Søyseth V; Omland T
    J Intern Med; 2015 Jul; 278(1):59-67. PubMed ID: 25495178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.